Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines

Vaccine

Volumn 26, Issue 45, 2008, Pages 5736-5740

  Hu, Alan Yung Chih ^a   Weng, Tsai Chuan ^a   Tseng, Yu Fen ^a   Chen, Yu Shuan ^a   Wu, Chia Hann ^a   Hsiao, Sigrid ^a   Chou, Ai Hsiang ^a   Chao, Hsin Ju ^a   Gu, Anna ^a   Wu, Suh Chin ^a,b   Chong, Pele ^a   Lee, Min Shi ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Bioreactor; Cell culture; Microcarrier; Pandemic influenza; Vaccine

Indexed keywords

ALUMINUM PHOSPHATE; HEMAGGLUTININ; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BIOREACTOR; CELL CULTURE; CELL STRAIN; CLADISTICS; CONTROLLED STUDY; CULTURE MEDIUM; DEVICE; DRUG MANUFACTURE; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; MICROCARRIER CULTURE; MOUSE; NONHUMAN; PARAMETER; PRIORITY JOURNAL; PROTEIN PURIFICATION; SERUM; SPINNER FLASK; VIRUS INACTIVATION;

ANIMALS; ANTIBODIES, VIRAL; BIOREACTORS; BIOTECHNOLOGY; CELL COUNT; CELL CULTURE TECHNIQUES; CELL LINE; DOGS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; KIDNEY; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; VIRUS CULTIVATION;

EID: 52949103690     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.015     Document Type: Article

References (24)

1. World Health Organization. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines, March 2007. Wkly Epidemiol Rec 82 (2007) 164-167
2. World Health Organization. Global pandemic influenza action plan to increase vaccine supply (2006), WHO, Geneva
3. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., and Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16 (1998) 960-968
4. Palache A.M., Scheepers H.S., de Regt V., et al. Safety, reactogenicity and immunogenicity of Madin Darby canine kidney cell-derived inactivated influenza subunit vaccine: a meta-analysis of clinical studies. Dev Biol Stand 98 (1999) 115-125
5. Audsley J.M., and Tannock G.A. The role of cell culture vaccines in the control of the next influenza pandemic. Expert Opin Biol Ther 4 (2004) 709-717
6. Nicolson C., Major D., Wood J.M., and Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23 (2005) 2943-2952
7. Horimoto T., Murakami S., Muramoto Y., et al. Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology 366 (2007) 23-27
8. Chong P, Liu C, Chou F, et al. Emergency production of avian flu vaccines. In: Options for the control of influenza VI. Toronto, Canada, 2007:P291.
9. Kistner O., Howard M.K., Spruth M., et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25 (2007) 6028-6036
10. World Health Organization. WHO manual on animal influenza diagnosis and surveillance (2002), WHO, Geneva
11. Hehme N., Engelmann H., Kuenzel W., Neumeier E., and Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103 (2004) 163-171
12. Hehme N., Engelmann H., Kunzel W., Neumeier E., and Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 191 (2002) 203-208
13. Nicholson K.G., Colegate A.E., Podda A., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001) 1937-1943
14. Treanor J.J., Wilkinson B.E., Masseoud F., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 (2001) 1732-1737
15. Wood J.M., Schild G.C., Newman R.W., and Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 5 (1977) 237-247
16. BioPharm. Conference on producing vaccines for developing nations. BioPharm International, 2002:8.
17. Cha L., Gao J., Hou J.Y., et al. Preparation of rabies vaccine for human use by cell culture in bioreactor. Chin J Biol 19 (2006) 288-290
18. Stephenson I. H5N1 vaccines: how prepared are we for a pandemic?. Lancet 368 (2006) 965-966
19. Tree J.A., Richardson C., Fooks A.R., Clegg J.C., and Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19 (2001) 3444-3450
20. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1343-1351
21. Bresson J.L., Perronne C., Launay O., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
22. Lin J., Zhang J., Dong X., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 (2006) 991-997
23. Leroux-Roels I., Borkowski A., Vanwolleghem T., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007) 580-589
24. Vajo Z., Kosa L., Visontay I., Jankovics M., and Jankovics I. Inactivated whole virus influenza A (H5N1) vaccine. Emerg Infect Dis 13 (2007) 807-808